April 22, 2024

Geschäftsanbahnungsreise Biotech – Vereinigtes Königreich (London & Cambridge)

Geschäftsanbahnungsreise Biotech – Vereinigtes Königreich (London & Cambridge)
Go back

Geschäftsanbahnungsreise Biotech – Vereinigtes Königreich (London & Cambridge)  

Target group:  German companies from the Biotech sector

Dates:  11–14 May 2026

Target region:  United Kingdom, London, Cambridge and Stevenage

Local partner onsite:  Life Science Integrates (LSI)

Organizer:  Market Entry Program of the Federal Ministry for Economic Affairs and Energy
(BMWE)

Registration deadline:  31 January 2026 (or until all spots are filled)

Vom 11.05. bis zum 14.05.2026 führt in2newmarkets, im Auftrag des Bundesministeriums für Wirtschaft und
Energie (BMWE), eine Geschäftsanbahnungsreise ins Vereinigte Königreich durch. Es handelt sich dabei um eine
projektbezogene Fördermaßnahme. Sie ist Bestandteil der Exportinitiative Gesundheitswirtschaft und wird im
Rahmen des Markterschließungsprogramms für KMU durchgeführt. Zielgruppe sind vorwiegend kleine und mittlere deutsche Unternehmen (KMU).

Anmeldeunterlagen GAB UK Biotech

Infoletter GAB Biotech UK 2026

register now

Our latest News

discover more
New bioRN Members of 2025

New bioRN Members of 2025

In 2025, the bioRN cluster experienced a strong and dynamic expansion as many new members joined its growing network. This influx of new companies and institutions further strengthened the cluster’s expertise, diversity, and innovative power. The cluster is now pleased to introduce these new members and highlight the diverse capabilities they bring, further reinforcing its […]

read more
ariadne.ai Secures Invest BW Funding to Build “TumorTwin”: The First Digital Twin for Glioblastoma Powered by Morphometric Spatial Multi-Omics

ariadne.ai Secures Invest BW Funding to Build “TumorTwin”: The First Digital Twin for Glioblastoma Powered by Morphometric Spatial Multi-Omics

HEIDELBERG, Germany – January 9, 2026 – ariadne.ai (Germany) GmbH today announced it has been awarded €518,000 in non-dilutive funding from the State of Baden- Württemberg (Invest BW) for its ambitious new project, TumorTwin. The project aims to revolutionize the treatment of Glioblastoma, one of the deadliest and most aggressive brain tumors, by creating a […]

read more
AMGEN acquires Dark Blue Therapeutics, bolstering oncology pipeline

AMGEN acquires Dark Blue Therapeutics, bolstering oncology pipeline

Acquisition Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia THOUSAND OAKS, Calif., Jan. 6, 2026 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced its acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom advancing first-in-class, small molecule-targeted protein degraders for oncology, in a transaction valued at up to $840 million.   The acquisition adds to Amgen’s […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp